ORIC is a pharmaceutical company dedicated to discovering and developing therapies towards overcoming resistance in cancer. It offers a small molecule antagonist of the glucocorticoid receptor, which has been implicated in resistance to various treatment modalities, including chemotherapy, immunotherapy, and anti-hormonal therapy, and across multiple cancers.